|
1
|
Altekruse SF, Henley SJ, Cucinelli JE and
McGlynn KA: Changing hepatocellular carcinoma incidence and liver
cancer mortality rates in the United States. Am J Gastroenterol.
109:542–553. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ma J, Siegel RL, Islami F and Jemal A:
Temporal trends in liver cancer mortality by educational attainment
in the United States, 2000–2015. Cancer. 125:2089–2098. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Anwanwan D, Singh SK, Singh S, Saikam V
and Singh R: Challenges in liver cancer and possible treatment
approaches. Biochim Biophys Acta Rev Cancer. 1873:1883142020.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yeo W, Mok TS, Zee B, Leung TW, Lai PB,
Lau WY, Koh J, Mo FK, Yu SC, Chan AT, et al: A randomized phase III
study of doxorubicin versus cisplatin/interferon
alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy
for unresectable hepatocellular carcinoma. J Natl Cancer Inst.
97:1532–1538. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bruix J, Reig M and Sherman M:
Evidence-based diagnosis, staging, and treatment of patients with
hepatocellular carcinoma. Gastroenterology. 150:835–853. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhu AX, Kudo M, Assenat E, Cattan S, Kang
YK, Lim HY, Poon RT, Blanc JF, Vogel A, Chen CL, et al: Effect of
everolimus on survival in advanced hepatocellular carcinoma after
failure of sorafenib: The EVOLVE-1 randomized clinical trial. JAMA.
312:57–67. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mansoori B, Mohammadi A, Davudian S,
Shirjang S and Baradaran B: The different mechanisms of cancer drug
resistance: A brief review. Adv Pharm Bull. 7:339–348. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rajabalian S: Methanolic extract of
Teucrium polium L. potentiates the cytotoxic and apoptotic effects
of anticancer drugs of vincristine, vinblastine and doxorubicin
against a panel of cancerous cell lines. Exp Oncol. 30:133–138.
2008.PubMed/NCBI
|
|
10
|
Khanna C, Rosenberg M and Vail DM: A
review of paclitaxel and novel formulations including those
suitable for use in dogs. J Vet Intern Med. 29:1006–1012. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mukherjee AK, Basu S, Sarkar N and Ghosh
AC: Advances in cancer therapy with plant based natural products.
Curr Med Chem. 8:1467–1486. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gokduman K: Strategies targeting DNA
Topoisomerase I in cancer chemotherapy: Camptothecins, nanocarriers
for camptothecins, organic non-camptothecin compounds and metal
complexes. Curr Drug Targets. 17:1928–1939. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fu XY, Zhang S, Wang K, Yang MF, Fan CD
and Sun BL: Caudatin inhibits human glioma cells growth through
triggering DNA damage-mediated cell cycle arrest. Cell Mol
Neurobiol. 35:953–959. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li Y, Xiong H and Yang DQ: Functional
switching of ATM: Sensor of DNA damage in proliferating cells and
mediator of Akt survival signal in post-mitotic human neuron-like
cells. Chin J Cancer. 31:364–372. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Trenti A, Zulato E, Pasqualini L,
Indraccolo S, Bolego C and Trevisi L: Therapeutic concentrations of
digitoxin inhibit endothelial focal adhesion kinase and
angiogenesis induced by different growth factors. Br J Pharmacol.
174:3094–3106. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Patel S: Plant-derived cardiac glycosides:
Role in heart ailments and cancer management. Biomed Pharmacother.
84:1036–1041. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang YZ, Chen X, Fan XX, He JX, Huang J,
Xiao DK, Zhou YL, Zheng SY, Xu JH, Yao XJ, et al: Compound library
screening identified cardiac glycoside digitoxin as an effective
growth inhibitor of gefitinib-resistant non-small cell lung cancer
via downregulation of α-tubulin and inhibition of microtubule
formation. Molecules. 21:3742016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lopez-Lazaro M: Digitoxin as an anticancer
agent with selectivity for cancer cells: Possible mechanisms
involved. Expert Opin Ther Targets. 11:1043–1053. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee DH, Lee CS, Kim DW, Ae JE and Lee TH:
Digitoxin sensitizes glioma cells to TRAIL-mediated apoptosis by
upregulation of death receptor 5 and downregulation of survivin.
Anticancer Drugs. 25:44–52. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu M, Feng LX, Sun P, Liu W, Mi T, Lei M,
Wu W, Jiang B, Yang M, Hu L, et al: Knockdown of apolipoprotein E
enhanced sensitivity of Hep3B cells to cardiac steroids via
regulating Na+/K+-ATPase signalosome. Mol Cancer Ther.
15:2955–2965. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pollard BS, Suckow MA, Wolter WR, Starr
JM, Eidelman O, Dalgard CL, Kumar P, Battacharyya S, Srivastava M,
Biswas R, et al: Digitoxin inhibits
epithelial-to-mesenchymal-transition in hereditary castration
resistant prostate cancer. Front Oncol. 9:6302019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lopez-Lazaro M, Pastor N, Azrak SS, Ayuso
MJ, Austin CA and Cortes F: Digitoxin inhibits the growth of cancer
cell lines at concentrations commonly found in cardiac patients. J
Nat Prod. 68:1642–1645. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang QF, Dalgard CL, Eidelman O, Jozwik C,
Pollard BS, Srivastava M and Pollard HB: Digitoxin induces
apoptosis in cancer cells by inhibiting nuclear factor of activated
T-cells-driven c-MYC expression. J Carcinog. 12:82013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee DH, Cheul Oh S, Giles AJ, Jung J,
Gilbert MR and Park DM: Cardiac glycosides suppress the maintenance
of stemness and malignancy via inhibiting HIF-1α in human glioma
stem cells. Oncotarget. 8:40233–40245. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yao N, Wang C, Hu N, Li Y, Liu M, Lei Y,
Chen M, Chen L, Chen C, Lan P, et al: Inhibition of
PINK1/Parkin-dependent mitophagy sensitizes multidrug-resistant
cancer cells to B5G1, a new betulinic acid analog. Cell Death Dis.
10:2322019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Paruthiyil S, Cvoro A, Tagliaferri M,
Cohen I, Shtivelman E and Leitman DC: Estrogen receptor β causes a
G2 cell cycle arrest by inhibiting CDK1 activity through the
regulation of cyclin B1, GADD45A, and BTG2. Breast Cancer Res
Treat. 129:777–784. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Deng LJ, Peng QL, Wang LH, Xu J, Liu JS,
Li YJ, Zhuo ZJ, Bai LL, Hu LP, Chen WM, et al: Arenobufagin
intercalates with DNA leading to G2 cell cycle arrest via ATM/ATR
pathway. Oncotarget. 6:34258–34275. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Löbrich M, Shibata A, Beucher A, Fisher A,
Ensminger M, Goodarzi AA, Barton O and Jeggo PA: gammaH2AX foci
analysis for monitoring DNA double-strand break repair: Strengths,
limitations and optimization. Cell Cycle. 9:662–669. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Durocher D and Jackson SP: DNA-PK, ATM and
ATR as sensors of DNA damage: Variations on a theme? Curr Opin Cell
Biol. 13:225–231. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Smith J, Tho LM, Xu N and Gillespie DA:
The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and
cancer. Adv Cancer Res. 108:73–112. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kastan MB and Bartek J: Cell-cycle
checkpoints and cancer. Nature. 432:316–323. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao H and Piwnica-Worms H: ATR-mediated
checkpoint pathways regulate phosphorylation and activation of
human Chk1. Mol Cell Biol. 21:4129–4139. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kroemer G, Galluzzi L and Brenner C:
Mitochondrial membrane permeabilization in cell death. Physiol Rev.
87:99–163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Deng LJ, Hu LP, Peng QL, Yang XL, Bai LL,
Yiu A, Li Y, Tian HY, Ye WC and Zhang DM: Hellebrigenin induces
cell cycle arrest and apoptosis in human hepatocellular carcinoma
HepG2 cells through inhibition of Akt. Chem Biol Interact.
219:184–194. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhu YJ, Zheng B, Wang HY and Chen L: New
knowledge of the mechanisms of sorafenib resistance in liver
cancer. Acta Pharmacol Sin. 38:614–622. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ceballos MP, Rigalli JP, Cere LI, Semeniuk
M, Catania VA and Ruiz ML: ABC Transporters: Regulation and
association with multidrug resistance in hepatocellular carcinoma
and colorectal carcinoma. Curr Med Chem. 26:1224–1250. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sun W, Chen X, Xie C, Wang Y, Lin L, Zhu K
and Shuai X: Co-Delivery of doxorubicin and Anti-BCL-2 siRNA by
pH-responsive polymeric vector to overcome drug resistance in in
vitro and in vivo HepG2 hepatoma model. Biomacromolecules.
19:2248–2256. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gao DY, Lin Ts T, Sung YC, Liu YC, Chiang
WH, Chang CC, Liu JY and Chen Y: CXCR4-targeted lipid-coated PLGA
nanoparticles deliver sorafenib and overcome acquired drug
resistance in liver cancer. Biomaterials. 67:194–203. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Marin JJG, Briz O, Herraez E, Lozano E,
Asensio M, Di Giacomo S, Romero MR, Osorio-Padilla LM,
Santos-Llamas AI, et al: Molecular bases of the poor response of
liver cancer to chemotherapy. Clin Res Hepatol Gastroenterol.
42:182–192. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Prassas I, Karagiannis GS, Batruch I,
Dimitromanolakis A, Datti A and Diamandis EP: Digitoxin-induced
cytotoxicity in cancer cells is mediated through distinct kinase
and interferon signaling networks. Mol Cancer Ther. 10:2083–2093.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Feng Q, Leong WS, Liu L and Chan WI:
Peruvoside, a cardiac glycoside, induces primitive myeloid leukemia
Cell Death. Molecules. 21:5342016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Felth J, Rickardson L, Rosén J, Wickström
M, Fryknäs M, Lindskog M, Bohlin L and Gullbo J: Cytotoxic effects
of cardiac glycosides in colon cancer cells, alone and in
combination with standard chemotherapeutic drugs. J Nat Prod.
72:1969–1974. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xiao Y, Yan W, Guo L, Meng C, Li B, Neves
H, Chen PC, Li L, Huang Y, Kwok HF and Lin Y: Digitoxin synergizes
with sorafenib to inhibit hepatocelluar carcinoma cell growth
without inhibiting cell migration. Mol Med Rep. 15:941–947. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nolte E, Wach S, Silva IT, Lukat S, Ekici
AB, Munkert J, Müller-Uri F, Kreis W, Oliveira Simões CM, Vera J,
et al: A new semisynthetic cardenolide analog 3β-[2-(1-amantadine)-
1-on-ethylamine]-digitoxigenin (AMANTADIG) affects G2/M cell cycle
arrest and miRNA expression profiles and enhances proapoptotic
survivin-2B expression in renal cell carcinoma cell lines.
Oncotarget. 8:11676–11691. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Elbaz HA, Stueckle TA, Wang HY, O'Doherty
GA, Lowry DT, Sargent LM, Wang L, Dinu CZ and Rojanasakul Y:
Digitoxin and a synthetic monosaccharide analog inhibit cell
viability in lung cancer cells. Toxicol Appl Pharmacol. 258:51–60.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu JS, Huo CY, Cao HH, Fan CL, Hu JY,
Deng LJ, Lu ZB, Yang HY, Yu LZ, Mo ZX and Yu ZL: Aloperine induces
apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma
cells through the PI3K/Akt signaling pathway. Phytomedicine.
61:1528432019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bloom J and Cross FR: Multiple levels of
cyclin specificity in cell-cycle control. Nat Rev Mol Cell Biol.
8:149–160. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Nurse P: A long twentieth century of the
cell cycle and beyond. Cell. 100:71–78. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fisher DL and Nurse P: A single fission
yeast mitotic cyclin B p34cdc2 kinase promotes both S-phase and
mitosis in the absence of G1 cyclins. EMBO J. 15:850–860. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hayles J, Fisher D, Woollard A and Nurse
P: Temporal order of S phase and mitosis in fission yeast is
determined by the state of the p34cdc2-mitotic B cyclin complex.
Cell. 78:813–822. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gould KL and Nurse P: Tyrosine
phosphorylation of the fission yeast cdc2+ protein kinase regulates
entry into mitosis. Nature. 342:39–45. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
He YC, He L, Khoshaba R, Lu FG, Cai C,
Zhou FL, Liao DF and Cao D: Curcumin nicotinate selectively induces
cancer cell apoptosis and cycle arrest through a p53-mediated
mechanism. Molecules. 24:41792019. View Article : Google Scholar
|
|
53
|
Żuryń A, Litwiniec A, Safiejko-Mroczka B,
Klimaszewska- Wiśniewska A, Gagat M, Krajewski A, Gackowska L and
Grzanka D: The effect of sulforaphane on the cell cycle, apoptosis
and expression of cyclin D1 and p21 in the A549 non-small cell lung
cancer cell line. Int J Oncol. 48:2521–2533. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lee ST, Lee JY, Han CR and Kim YH, Jun do
Y, Taub D and Kim YH: Dependency of 2-methoxyestradiol-induced
mitochondrial apoptosis on mitotic spindle network impairment and
prometaphase arrest in human Jurkat T cells. Biochem Pharmacol.
94:257–269. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Mak JP, Man WY, Ma HT and Poon RY:
Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing
cell growth stimulation and apoptosis. Oncotarget. 5:10546–10557.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Rong JJ, Hu R, Song XM, Ha J, Lu N, Qi Q,
Tao L, You QD and Guo QL: Gambogic acid triggers DNA damage
signaling that induces p53/p21(Waf1/CIP1) activation through the
ATR-Chk1 pathway. Cancer Lett. 296:55–64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Laiho M and Latonen L: Cell cycle control,
DNA damage checkpoints and cancer. Ann Med. 35:391–397. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Piacente S, Masullo M, De Néve N, Dewelle
J, Hamed A, Kiss R and Mijatovic T: Cardenolides from Pergularia
tomentosa display cytotoxic activity resulting from their potent
inhibition of Na+/K+-ATPase. J Nat Prod. 72:1087–1091. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Mijatovic T, Dufrasne F and Kiss R:
Cardiotonic steroids-mediated targeting of the Na(+)/K(+)-ATPase to
combat chemoresistant cancers. Curr Med Chem. 19:627–646. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Xu ZW, Wang FM, Gao MJ, Chen XY, Hu WL and
Xu RC: Targeting the Na(+)/K(+)-ATPase alpha1 subunit of hepatoma
HepG2 cell line to induce apoptosis and cell cycle arresting. Biol
Pharm Bull. 33:743–751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Mijatovic T, Dufrasne F and Kiss R:
Na+/K+-ATPase and cancer. Pharm Pat Anal. 1:91–106. 2012.
View Article : Google Scholar : PubMed/NCBI
|
